Leaders from across medical regulatory bodies are steering transformative dialogue and decisions within the HMA-EMA joint Network Data Steering Group. With emerging topics such as real-world evidence (RWE) and artificial intelligence (AI) in focus, the group convenes regularly to set priorities and drive impactful initiatives. On July 17, 2025, a pivotal meeting took place via Webex, co-chaired by Karl Broich and Peter Arlett. Their commitment to robust regulation standards is shaping modern healthcare landscapes, addressing pivotal challenges and strategic opportunities within the European Medicines Agency (EMA) and associated networks.
Advancements in Real-World Evidence
Patrice Verpillat spearheaded discussions on RWE, elaborating on the third annual experience report, which highlighted pathways such as DARWIN EU® and framework-contracted studies. The report delves into RWE’s value in regulatory decisions and identifies future steps to enhance operational efficiency. Essential updates included the comprehensive EMA’s Catalogues of RWD sources and quality frameworks that aid methodological advances.
Decision-Making Process for Clinical Study Data Pilot
Flora Musuamba Tshinanu outlined the progress and success of the clinical study data pilot, detailing its role in streamlining new marketing authorization applications. After a successful first phase, the second stage aims to refine visual data analysis to boost decision-making speed and accuracy. The initiative, which originally launched in 2022, continues to harness insightful data analytics to enhance regulatory frameworks.
Prioritized bullet points from the meeting included:
– Importance of data quality and representativeness for effective RWE use.
– Rapid response mechanisms for queries to optimize DARWIN EU’s utility.
– Training necessity for clear, actionable queries by assessors.
– Network collaboration as crucial for shared understanding and efficiency.
In the concluding sections of the meeting, the group reinforced support for the refined change management strategies, emphasizing targeted actions and stakeholder engagement. The group identified essential areas for AI change management, pivoting on national responsibilities for seamless integration into existing frameworks. A focused call to action saw increased engagement with various clinical study data and AI initiatives, aiming to harness their potential to redefine regulatory landscapes.
In deploying these strategies, a concerted emphasis on collaborative engagements within the network was highlighted, setting a precedent for how regulatory bodies can streamline processes through technological advances. The alignment of digital data tools is poised to offer integrative frameworks useful for policymakers, industry professionals, and scientific assessors. Progress in RWE and AI is not just an administrative victory but a frontline endeavor that promises to reshape public health, empowering regulatory bodies to navigate challenges adeptly and efficiently.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
